Olin Corporation (NYSE: OLN) — A Leveraged Call on Chlorine, With Winchester as the Airbag

Date: June 9, 2026 Analytical framework: competitive-advantage lens; Greenwald “Competition Demystified” + Marathon “Capital Returns” Security: Olin Corporation, common stock, NYSE: OLN Price (2026-06-09): ~$24.51 · Shares: ~114.6M · Equity mkt cap: ~$2.8B · Net debt: ~$3.3B · EV: ~$5.9–6.1B (EV ≈ 2.1× equity) Sector: Basic Materials — Commodity Chemicals (chlor-alkali & vinyls, epoxy) + Winchester ammunition CIK: 0000074303 · FY-end: December · CEO: Kenneth T. Lane (since Mar 2024) · CFO: Todd A. Slater

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice. The body of this article (Sections 1–15) is deliberately position-free: it takes no position, sets no price target, and carries no recommendation. The only opinion appears in this clearly-labeled block.

Verdict: SPECULATIVE BUY — but only for risk-tolerant capital and only position-sized like the option it is. Olin is a deep, leveraged call on a chlor-alkali cycle turn, trading at a genuine discount to my base case (~$42) with violently convex payoffs (bear ~$10, base ~$42, bull ~$68). The asymmetry from ~$24.50 actually favors the long — IF you believe the cycle clears the balance sheet before the balance sheet clears the equity. That “if” is the whole game. Fair-value base zone ~$38–44; the convexity is attractive below ~$25; I would not chase it above ~$30.

Tag: “A leveraged call on chlorine — with Winchester as the airbag.”

The thesis in two paragraphs. Olin is the same commodity-chemical-trough story as LyondellBasell, but smaller, more concentrated, far more financially leveraged, and far more hated (11.7% of float short vs. LYB’s ~4%). The chlor-alkali (ECU) cycle is at a genuine, multi-year Marathon-style bottom — seven-plus trough quarters, North American chlorine index values above every prior trough, Western capacity rationalizing (Europe/LatAm/US closures; OxyChem sold to Berkshire in January 2026), and a 2026 Iran-war supply shock taking 6–9% of global vinyls capacity offline and steepening the cost curve toward US Gulf Coast producers. Layer on real self-help (“Beyond 250,” +$100–120M in 2026 toward >$250M by 2028), a disciplined, conservative, well-covered dividend, and — critically — Winchester, an iconic-brand ammunition duopoly with a Lake City government-arsenal annuity and a ~$1.33B contracted backlog that is the closest thing to a real moat Olin owns. Strip the chemicals to mid-cycle and the parts (CAPV at ~5× + Winchester at ~9× + a recovering Epoxy) sum above the traded enterprise value. The market at $24.50 is pricing only ~65–80% of a normal mid-cycle recovery — a discount, where LYB at $63 is priced for a near-full one.

The catch is the balance sheet, and it is a big catch. Net debt of ~$3.3B sits senior to a ~$2.8B equity sliver; EV is ~2.1× the equity, so a ~2× swing in EBITDA produces a ~7× swing in the stock. That convexity is the entire appeal and the entire danger. In February 2026 Olin had to amend its credit facility into a secured package — pledging substantially all personal property, accepting covenant relief through September 2027, pricing step-ups, and restrictions that freeze buybacks and cap the dividend — a near-covenant-breach, lender-protection move, not a routine refresh. Ratings have slipped out of investment grade (Fitch BB+, S&P BB, Moody’s Ba1). Goodwill of $1.43B (mostly CAPV) faces a Q4-2026 triennial impairment test with CAPV already segment-loss-making; a ~$185M Shintech litigation payment drains 2026 cash; and ~$1.7B matures in 2029–30 to be refinanced as secured sub-investment-grade. This is not a compounder and it is not a sleep-at-night holding — it is a special-situation, capital-cycle call option where the downside is a 60%+ drawdown (and, in the genuine tail, a restructuring) and the upside is a double-plus. I lean long because the cycle signals are real, Winchester provides a hard-asset floor, and the price already embeds a discount — but this is a sized-small, eyes-open position, not a core one. Conviction: medium.

• What flips me decisively bullish: ECU values and operating rates climbing on rationalization (Western closures + OxyChem/Berkshire supply discipline), not war noise — realized (non-war) EBITDA tracking toward $1.3–1.4B and visible deleveraging toward ~2.5×. That makes the base case the floor, not the target.
• What flips me bearish: the war premium fades in H2-2026 with no demand behind it, EBITDA sticks at $0.7–0.9B, a goodwill impairment and a dividend cut arrive, and the 2029–30 maturity wall looms with leverage still ~4–5× — the path where the balance sheet clears the equity first.

1. Executive Summary

Olin is the world’s largest chlor-alkali producer, a fully-integrated epoxy producer, and — through Winchester — one of the two dominant US ammunition manufacturers and operator of the US Army’s Lake City arsenal. Roughly 74% of 2025 sales are commodity chemicals (Chlor Alkali Products & Vinyls 54%, Epoxy 20%) and 26% is Winchester ammunition. The investment question is not business quality — across a full cycle the chemicals barely earn their cost of capital — but timing and capital structure: whether this is the right point in a violent capital cycle to own a highly-levered survivor with one genuinely differentiated franchise.

Where we are in the cycle (Fact/Interpretation). 2025 was a deep trough. Adjusted EBITDA fell to ~$0.62B from a 2021–22 peak near $2.5B; the company posted a GAAP net loss of $(100.5)M (EPS $(0.88)); CAPV segment income collapsed from $1,181M (2022) to $181M (2025) and turned negative in Q1-2026; Epoxy lost money for a fourth straight year (−$103.5M); and Winchester income fell −72% to $67.7M. The cause is a textbook Marathon capital-cycle bust in chlor-alkali, with the self-correction now visible — seven-plus trough quarters, Western capacity rationalization, NA chlorine index above prior troughs, and OxyChem’s January-2026 sale to Berkshire Hathaway raising hopes of supply discipline. China, however, continues to net-add caustic capacity, so the recovery is real but uneven.

The exogenous wildcard. An Iran/Middle East war beginning in late February 2026 caused Asian vinyls force majeures (management cites 6–9% of global vinyls capacity impacted), spiking EDC/caustic prices and steepening the cost curve toward US Gulf Coast producers. Q2-2026 EBITDA is guided to $160–200M (a sharp jump off the ~$86M Q1-2026 base). This windfall is transient and must be normalized out of any through-cycle estimate.

The defining feature — leverage. Net debt of ~$3.3B against a ~$2.8B equity market cap makes EV ~2.1× the equity; the stock is a leveraged call on the cycle. In February 2026 Olin amended its credit facility into a secured structure with covenant relief through September 2027 and explicit restrictions on dividends-above-regular, buybacks, and asset sales — a near-distress, lender-protection package. Ratings are sub-investment-grade (Fitch BB+, S&P BB, Moody’s Ba1). Goodwill of $1.43B faces a Q4-2026 impairment test; ~$1.7B matures in 2029–30.

Capital allocation (Verdict: pro-cyclical, worse than peers due to leverage). Olin spent ~$2.66B on buybacks 2021–2025, the bulk ($1.35B at ~$53/share) at the 2022 cycle peak, debt-funded — then was forced to freeze returns and pledge collateral at the trough. The dividend (~$0.80, ~2.7× FCF-covered, 398 consecutive quarters) is the one conservative strand; small Winchester bolt-ons (AMMO Inc., White Flyer) are disciplined; the comp plan lacks any ROIC or leverage metric.

Valuation (embedded expectations). At $24.51 the market prices only ~$0.95–1.1B of through-cycle EBITDA at a sub-IG ~5.5–6.5× multiple — ~65–80% of a normalized ~$1.4B, i.e., a discount to mid-cycle (vs. LYB priced at a near-full recovery). Base-case fair value ~$42 (+71%); bear ~$10 (−61%); bull ~$68 (+176%). The leverage delivers ~7× equity convexity on a ~2× EBITDA swing.

Bottom line. A higher-risk, higher-convexity expression of the commodity-chem-trough thesis than LYB: cheaper for a reason (leverage, sub-IG, covenant amendment, goodwill and refinancing tails), more convex for a reason, with Winchester as a genuine quality ballast and hidden value. The body below carries no recommendation; the analysis supports a “special-situation, watch-the-balance-sheet” posture and close tracking of the Section 14 falsification tests.

2. Business Overview

What Olin does (Fact). Olin converts salt, electricity, and hydrocarbons into basic chemicals, and brass/lead/propellant into ammunition. It reports three segments:

The ECU mechanic (Fact). Electrolysis of brine co-produces chlorine and caustic soda in a fixed ~1.0:1.1 ratio plus hydrogen — the “electrochemical unit.” Olin cannot make one without the other, and the two have independent demand curves, so segment profitability is governed by the combined ECU value. Currently caustic soda is the stronger side (alumina, pulp/paper, water treatment) while chlorine/vinyls/PVC is weak (construction-driven). Chlorine flows into EDC/VCM (PVC precursors), chlorinated organics, and bleach; Olin is one of the largest global merchant marketers of both EDC and caustic.

Revenue character / recurring vs. cyclical (Interpretation). CAPV and Epoxy are pure commodity — “price is one of the major supplier selection criteria” (10-K). Winchester’s military stream (Lake City, ~$1.33B backlog) is the only contracted forward revenue in the company; its commercial stream is brand-driven but gun-demand/election cyclical. So roughly three-quarters of revenue is price-taking commodity, and the most recurring/annuity-like piece is the Winchester defense book.

How the ECU actually earns (Interpretation). The economics are worth making concrete because they explain both the trough and the recovery mechanism. Because chlorine and caustic are produced in lockstep (~1:1.1) but demanded independently, the producer’s realized “ECU value” is the sum of what it can sell each co-product for, net of the cost of disposing of (or idling for) the weaker one. In the current trough, chlorine/vinyls demand (PVC → construction) is weak while caustic (alumina, pulp, water treatment) is firmer — so Olin’s value model is to idle rather than dump chlorine derivatives at distressed prices, accepting lower volume to defend the blended ECU. When the cycle turns, the operating leverage is violent in reverse: a producer running “not far above 50%” can lift volumes substantially with little incremental fixed cost, so a modest tightening in chlorine demand (e.g., the 2026 war-driven vinyls force majeures, or a construction recovery) flows almost entirely to EBITDA. This is the source of the equity’s operating convexity, which then compounds with the financial convexity of the ~$3.3B net debt — the two leverages stacked are why the scenario band is so wide.

Footprint (Fact). ~16M tons chlorine / ~17M tons caustic capacity (~14% of world capacity), the largest position globally; US Gulf Coast-centric, gas-advantaged power (~76% natural gas/hydro), ~73% salt internally sourced; 7,849 employees. Winchester operates the government-owned, contractor-operated (GOCO) Lake City Army Ammunition Plant.

Verdict. A scaled, integrated, US-feedstock-advantaged commodity chemical producer whose economics are governed by the ECU cycle, bolted to a genuinely differentiated ammunition franchise. The business is understandable and operationally well-run, but two-thirds-plus of it is a price-taker; segment quality ranges from the structurally-impaired Epoxy unit through the cost-advantaged-but-commodity CAPV engine to the moat-bearing Winchester franchise.

3. Industry Dynamics

Olin straddles three distinct industries; their quality and cycle positions differ sharply.

(1) Chlor-alkali/vinyls — bad industry, at a turning trough (Fact/Interpretation). The ECU’s joint-product economics mean a producer either idles capacity when one side is weak or floods the market with the weak co-product. Global capacity is ~53Mt caustic; North America is ~14% of world capacity. The cost curve runs US Gulf gas-advantaged < China coal-based < European high-energy, with the European/marginal producer setting the depressed floor. The capital cycle is turning: management cites a “seventh quarter in a row of trough demand,” NA chlorine index values “higher than any prior trough,” active Western rationalization (Europe/LatAm/US closures), “limited additional capacity,” and the January-2026 sale of OxyChem (NA’s #2) to Berkshire Hathaway — a potential supply-discipline catalyst. Counter-signal: China added ~1.6Mt of caustic capacity in 2025 and keeps building; caustic is forecast merely range-bound (~$690–740/MT FOB) in 2026. So the turn is real but uneven — a regional (Western) rationalization against continued Chinese additions.

(2) Epoxy — structurally impaired (Fact). Chronic global (especially Chinese) oversupply; weak construction/wind/electronics demand; and — decisively — the US AD/CVD case against China was terminated on April 30, 2025 on a negligibility finding, with duties applied only to Korea/Taiwan/Thailand. The dominant subsidized exporter (China) escaped, and the parallel European case also disappointed. Epoxy is Olin’s analog to LYB’s structurally-disadvantaged European O&P: a value-destroying drag surviving on self-help (the “last integrated supplier in Europe,” a $40–50M European cost program, the Brazil Guarulhos closure, announced price increases) rather than industry recovery.

(3) Ammunition — the best of the three (Fact/Interpretation). US commercial ammo is effectively a duopoly (Winchester + The Kinetic Group, the former Vista brands bought by Czechoslovak Group in late 2024), where brand and distribution matter in a way they never do in chemicals. Commercial demand is cyclical (2025 NSSF-adjusted NICS 14.6M, −4.1% YoY; excise receipts down ~31% since 2022) but turning up, and tariffs as high as 50% have collapsed imports (formerly ~12% of US demand) — a structural share gift to domestic producers. The military stream is a durable annuity: Lake City (the sole US GOCO arsenal), multi-year Army contracts, the NGSW 6.8mm facility (completion ~late 2027), and NATO/Ukraine replenishment. Copper at record highs (~$6.71/lb in 2026) is the cost headwind.

Regulation (Interpretation). Energy/carbon costs advantage US gas-power producers and accelerate European chlor-alkali rationalization (helping survivors); PVC/chlorine and PFAS scrutiny is a latent industry risk. For ammunition, financial/ESG de-risking of firearms is a recurring overhang on multiple and capital access, offset by supportive 2nd-Amendment politics and tariff protection.

The capital-cycle mechanism in chlor-alkali (Interpretation). Marathon’s framework applies cleanly here. The 2021–22 super-cycle (Olin earned ~$2.5B EBITDA on pandemic-era tightness and the value model) generated returns that, in a normal industry, would have triggered a capacity-build wave. What makes the chlor-alkali setup more favorable than polyolefins is that the Western response was not a build wave but its opposite — because the marginal Western producer (European, energy-disadvantaged post-2022) was already underwater, the high returns accrued mostly to low-cost US incumbents while the high-cost capacity began to exit. The down-leg since 2022 has now run seven-plus quarters, and the self-correcting signals are textbook: NA chlorine index above prior troughs (the cost curve has shifted up as marginal supply leaves), explicit Western rationalization (European/LatAm/US closures), “limited additional capacity” by management’s account, and the OxyChem→Berkshire ownership change that markets read as a tilt toward cash-disciplined supply behavior. The asymmetry vs. polyolefins (LYB) is that chlor-alkali’s new capacity is concentrated in China for domestic consumption (coal-based vinyls), not export polyethylene, so the Western ECU market is less directly flooded — supporting the “NA index above prior troughs” observation. The caveat remains China: its continued caustic additions can cap the recovered mid-cycle even as the Western market tightens, which is why the base case normalizes EBITDA to ~$1.35B rather than back toward the ~$2.5B peak.

Verdict: a structurally below-average industry mix, but cyclically well-timed. The chemicals (74% of sales) are bad businesses — no pricing power, subsidized foreign entrants, capital-intensive, through-cycle returns near cost of capital — sitting at a genuine cyclical bottom that shows the classic Marathon turn-signals (multi-year trough, Western rationalization, prices above prior troughs, OxyChem changing hands), now amplified by a likely-transient war shock. Ammunition (26%) is a genuinely good business at a cyclical low turning up. The central falsification test, identical to LYB’s, is whether the chlor-alkali trough is turning via rationalization (durable) or merely war noise (transient).

4. Competitive Position

The chlor-alkali cost edge — real but shared (Fact/Interpretation). Olin is the world’s #1 chlor-alkali producer (~14% of global capacity), with a cost advantage rooted in US Gulf Coast gas-advantaged electricity (electricity is 40–60% of caustic production cost; ~76% of Olin’s power is gas/hydro), scale, integration, internal salt (~73%), and deep-water export access. This edge is real and it ties to a financial outcome (less margin compression than European/Asian peers in the trough). But it is a regional advantage shared with US peers OxyChem and Westlake, not a company-specific moat; it is inferior to no one structurally but distinguishes Olin only versus high-cost foreign producers; and management itself notes that rising US gas can erode it. By the Greenwald test this is a survivorship cost advantage, not a returns moat — the financial proof is that the world’s #1 low-cost producer still earned sub-cost-of-capital returns in 2024–25.

The “value-first” model — discipline, not a moat (Interpretation — the crux of the bull case). Olin’s signature is its value-over-volume commercial model: deliberately running chlor-alkali well below capacity (“not that far above 50%”) to defend ECU price rather than chase volume, treating itself as the swing producer. The bull case holds this is a structural advantage. Pressure-tested, it is disciplined capital-cycle behavior, not a Greenwald moat. The decisive evidence is BofA analyst Matthew DeYoe’s Q2-2025 challenge: the ECU index sat at ~186 (vs. ~200 in 2021), yet 2021 generated ~$2.1B of CAPV+Epoxy EBITDA against barely breakeven in 2025 — price stability with collapsed volume is not value creation. Management could only point to relative index stability while conceding “we are at trough demand levels.” The model held ECU index values through the trough (a genuine achievement) but did not prevent an earnings collapse, and it depends on competitor restraint Olin cannot enforce. It is the rational supply-side response to a glut (Marathon would approve of idling capacity), but it generates low returns on stranded assets — a tactic, not a moat.

Winchester — the one real, financially-tied advantage (Fact/Interpretation). Winchester is the closest thing to a moat Olin owns: a 160-year iconic brand, a US commercial duopoly position, real switching costs and incumbency in the Lake City GOCO arsenal (run since October 2020; the NGSW 6.8mm facility under construction), and a ~$1.33B contracted backlog (~81% shipping in 2026) — the only contracted forward revenue in the company. Tariff protection (imports collapsed under 50% duties) is a structural share gift. This advantage ties directly to a financial outcome and would deteriorate without the brand/contract — it is a genuine moat. The caveats: it is small (~26% of sales, only ~$68M trough income) and cyclical (income fell −72% in 2025), so it cannot anchor the whole company’s quality, and the moat is concentrated in the military/Lake City piece more than the commercial brand.

Sizing Winchester’s quality (Interpretation). Winchester deserves a closer look because it is the segment that most changes the character of the equity. The military/Lake City stream is the genuine annuity: Olin has operated the government-owned arsenal under a contractor agreement since October 2020, the relationship carries high switching costs (re-competing a live munitions base is rare and operationally fraught for the Army), and the forward book is contracted — a ~$1.33B backlog (~81% shipping in 2026) plus the NGSW 6.8mm next-generation-cartridge facility positioning Olin for the Army’s future small-arms standard. NATO-ally orders and Ukraine-driven replenishment extend the runway. The commercial stream is brand-and-distribution-driven (160-year “American Legend” brand, deep retailer/distributor relationships) and now tariff-protected (imports, formerly ~12% of US demand, have collapsed under duties up to 50%) — a structural domestic-share gift. The honest limits: Winchester is cyclical (commercial income tracks NICS/election demand and fell −72% in 2025), copper at record highs is compressing margins (management concedes 2026 pricing only “recovers cost”), and at ~$0.23B of mid-cycle EBITDA it is ~17% of the company. So Winchester is the airbag, not the engine: it provides a separable, defense-quality floor (worth ~$1.8–2.3B at an 8–10× multiple — see Section 10) that materially de-risks the equity’s downside, but it is too small to drive the upside, which still depends on the chlor-alkali cycle.

Epoxy — impaired, no moat (Fact). Structurally oversupplied, China-import-pressured, no trade relief (the April-2025 case failure), four straight loss years. A shrink-to-survive drag, directly analogous to LYB’s European O&P. The one nuance worth crediting: Olin’s claim to be “the last integrated supplier of epoxy in Europe” means that, post-Western rationalization, the survivors may capture a local supply-security premium — but that is a thin, regulation-and-rationalization-dependent reed, not a moat, and the Q1-2026 “return to profitability” is one self-help-driven quarter into a still-weak market, not evidence of structural recovery.

Verdict: no durable company-specific moat in the chemicals (~74% of revenue); a genuine but small moat in Winchester. CAPV is a survivorship cost advantage shared with US peers; the value-model is disciplined cyclicality, not pricing power (it held ECU index values but delivered sub-cost-of-capital returns); Epoxy is impaired. The only advantage that clearly ties to a financial outcome that would deteriorate without it is Winchester’s brand + Lake City contracted franchise — and it is too small to define the equity. Said plainly: this is a leveraged commodity cyclical with a quality ammunition ballast, not a quality compounder.

5. Growth History and Forward Opportunities

History (Fact). Revenue is cyclical, not secular: ~$6.1B (2019) → ~$8.9B (2021) → ~$9.4B (2022 peak) → ~$6.5–6.8B (2024–25). The swings are ECU price and Epoxy margin, not volume. There is no organic unit-growth engine; per-share metrics were driven by buybacks (share count 163M → 115M) rather than top-line expansion. The one real acquired-growth story is Winchester’s expansion into Lake City (2020) and bolt-ons (White Flyer 2023, AMMO Inc. 2025).

Forward opportunities (Fact/Interpretation), in descending credibility:

1. Cyclical chlor-alkali recovery (the real upside): mean reversion from ~$0.62B trough EBITDA toward ~$1.3–1.4B mid-cycle as Western rationalization + demand close the ECU gap into 2027–28. This is where the leverage convexity pays.
2. Self-help — “Beyond 250”: >$250M of cumulative structural cost savings by 2028 ($44M delivered 2025; +$100–120M targeted in 2026), via the Freeport operational-excellence pilot, headcount cuts (>300 in 2025), AI predictive maintenance, and supply contracts. Real and tracking, though 2025’s savings largely offset a ~$70M Dow Freeport stranded-cost headwind (“running to stand still”).
3. Winchester military ramp: the NGSW 6.8mm program, NATO/Ukraine replenishment, and a tariff-protected commercial recovery (mid-to-high-single-digit volume uplift expected). The highest-quality growth, but margin-constrained near-term by copper.
4. Epoxy self-help: the Stade (Germany) supply contract (~$40–50M) and European rightsizing toward a “last integrated supplier” position — loss-mitigation, not growth.

Verdict: low-quality, mean-reversion “growth.” No secular volume or pricing engine; the forward opportunity is a cyclical ECU recovery amplified by credible self-help and a Winchester defense ramp — an industry event Olin rides (chemicals) plus one genuine franchise build (Winchester/Lake City).

6. Financial Quality

The cyclical trajectory (Fact).

Segment income peak-to-trough: CAPV $1,181M (2022) → $181M (2025) → negative in Q1-2026; Epoxy $617M (2021) → −$103.5M (2025), four straight loss years; Winchester $412M (2021) → $67.7M (2025), −72% in 2025 alone. CAPV is the engine of the collapse; Winchester deflated alongside it (it is not counter-cyclical at the margin level). Q1-2026 was a net loss of $(83)M with CAPV segment-negative — the run-rate was still deteriorating before the war benefit.

Quality of earnings (Fact/Interpretation). One-time items distorting the trough: a $75M Q4-2025 Shintech/VCM litigation charge (+$36.1M in Q1-2026; ~$185M cash payment due H1-2026); ~$33M/yr restructuring; the Hurricane Beryl FY2024 hit (~−$126M) that flattered the 2024→2025 comp; a +$34.5M 45V hydrogen tax credit (policy-dependent); and ~$43M of FY2023 one-time gains. Normalized trough EBITDA is ~$0.55–0.65B. Note management reports Adjusted EBITDA (now also the performance-share metric from 2026) — which adds back restructuring and “non-recurring” items — so reconcile it to GAAP, which shows the $(100.5)M net loss.

The balance sheet — the central concern (Fact). Total debt ~$3.39B (incl. ~$0.31B finance leases), cash ~$0.17B, net debt ~$3.3B. Net debt/EBITDA is ~5.2× on trough EBITDA (vs. ~2× mid-cycle). The February 19, 2026 “First Amendment” is the defining event: the facility went unsecured → secured (subsidiary guarantees + liens on substantially all personal property), with covenant relief through September 30, 2027 (lower minimum coverage, higher maximum leverage), two pricing step-ups if leverage rises, and restrictions on new debt, dividends above the regular level, and asset sales (with mandatory term-loan paydown from asset-sale proceeds). This is a near-covenant-breach, lender-protection package — you do not pledge substantially all personal property and accept distribution handcuffs unless the leverage covenant was about to bind. Ratings are sub-IG: Fitch BB+, S&P BB, Moody’s Ba1 (investment grade lost in early 2026). Liquidity is ~$1.3B (revolver, covenant-governed), but the receivables-facility cushion is shrinking ($105.5M → $40M of incremental capacity in Q1-2026). The maturity wall is ~$1.7B in 2029–30 ($669M 2029, $1,043M 2030), to be refinanced as a secured sub-IG credit. Pension is only modestly underfunded (~$98M).

Goodwill / tangible equity (Fact/Interpretation). Goodwill is $1,427.6M (CAPV $1,276M, Epoxy $145M, Winchester $7M); after goodwill and intangibles, tangible equity is only ~$295M (~$2.5/share). The triennial quantitative impairment test is due Q4-2026, with CAPV segment-loss-making, Epoxy in chronic loss, and the stock down — a live impairment trigger, especially for the Epoxy goodwill and conceivably part of CAPV. An impairment would be non-cash but would compress tangible equity and covenant-EBITDA definitions.

Cash flow (Fact/Interpretation). FY2025 CFO $474M (~76% of EBITDA); capex ~$200–236M, well below D&A (~$520M, ~0.4×) — Olin is under-investing to protect FCF, borrowing from future reliability. FY2025 FCF ~$248M covered the $91.6M dividend ~2.7×, but the 2025 CFO was partly a working-capital release (reverses on recovery), and 2026 looks cash-consumptive (the ~$185M Shintech payment + Q1 loss + net borrowing). FY2026 capex is guided to ~$200M.

Through-cycle returns (Interpretation). Peak ROE ~50% (2021–22), trough negative (2025); through-cycle ROIC ~8–10% — i.e., the chemicals barely earn their cost of capital across a cycle, with Winchester the higher-return exception. Economics do not improve with scale in the chemicals — Olin is a price-taker.

Normalized earnings-power walk (Assumption; stated). Because every valuation conclusion rests on it, the mid-cycle bridge is laid out explicitly. Start with normalized Adjusted EBITDA of ~$1.35B — built from CAPV ~$0.95B (well below the ~$1.6B peak, reflecting Chinese caustic additions capping the recovered ECU), Winchester ~$0.23B (mid-cycle, not the $0.4B 2021 peak), and Epoxy ~$0.1B (a self-help-driven crawl back toward breakeven-plus, not the $0.6B 2021 peak, given the structural China overhang and the failed trade case). Subtract D&A ~$500M → EBIT ~$0.85B; subtract interest ~$190M (the cost of the ~$3.3B debt, rising at the margin under the amendment’s pricing step-ups) → pre-tax ~$0.66B; tax at ~25% → net income ~$0.45–0.55B, EPS ~$4.0–4.8 on ~115M shares. On the cash side: mid-cycle CFO ~$0.9–1.1B less ~$250–300M capex → FCF ~$0.6–0.8B, covering the ~$92M dividend ~7–9× and leaving ~$0.5B/year for deleveraging — the path management points to (toward <2× net leverage). The bear sensitivity is stark precisely because of the interest load: at ~$0.8B EBITDA, after ~$500M D&A and ~$190M interest, pre-tax income is only ~$110M and net income barely positive — the fixed ~$190M interest bill consumes most of a trough recovery, which is exactly why the equity is a leveraged option rather than a stable earner.

The covenant arithmetic (Interpretation). The February amendment’s relaxed maximum-net-leverage covenant is what stands between Olin and forced action. At ~$3.3B net debt, a covenant set around (illustratively) ~5.5–6.0× would be satisfied only down to ~$0.55–0.60B of covenant-EBITDA — barely above the FY2025 trough and below the ~$0.34B Q1-2026 annualized run-rate before the war benefit. That is the knife-edge the war windfall is currently helping Olin clear: the Q2-2026 guide of $160–200M restores comfortable headroom if it holds. Should the war premium fade before the structural recovery arrives, covenant-EBITDA could revisit the danger zone, and a goodwill impairment (which can reduce the EBITDA add-back base depending on definitions) would compound it. This is the mechanical reason the balance sheet, not the operating story, is the dominant variable.

Verdict: a high-financial-leverage, sub-IG cyclical at the trough. Reported numbers are genuinely weak (a GAAP net loss, CAPV segment-negative, four years of Epoxy losses), the balance sheet is in a managed-distress posture (secured amendment, sub-IG, shrinking cushion, a 2029–30 wall, a goodwill-impairment overhang), and the equity is a leveraged option on a recovery. The conservative, well-covered dividend and the modest pension are the offsets; the leverage is the story.

7. Capital Allocation

Verdict up front: pro-cyclical, and worse than peers because of the leverage. Olin bought back stock most aggressively at the top and was forced to pledge collateral at the bottom.

Buybacks (Fact). ~$2.66B spent 2021–2025, retiring ~52M shares (163M → 114.6M, ~30%), with the peak $1,350.7M deployed in 2022 at ~$53/share — the cycle’s earnings top — funded while carrying ~$3B of net debt. Spend then fell every year to a trivial $50.5M (~$23/share) in 2025. With the stock now ~$24.50, the bulk of that ~$2.66B was deployed above where the shares trade — textbook pro-cyclical value destruction (“buy high, can’t buy low”), debt-funded, and the proximate cause of today’s leverage. $1.95B of authorization remains but is covenant-frozen.

Dividend (Fact). $0.20/quarter = $0.80/year; the February 2026 declaration was the 397th consecutive quarterly payment, held through the trough; ~2.7× FCF-covered. The amendment bars increases above the regular dividend. A cut is not required and coverage is currently fine, but the dividend is the first discretionary lever if the trough deepens (the bear case). This conservatism on the dividend line is the one genuinely sound capital-return strand.

The February 2026 amendment (Fact — the critical event). Detailed in Section 6: secured, covenant relief through September 2027, pricing step-ups, and restrictions freezing buybacks and capping the dividend. It confirms the 2022-peak, debt-funded buyback left the balance sheet thin enough that a normal chemicals trough pushed Olin into a defensive, near-distress posture.

M&A / portfolio (Fact — the disciplined strand). Small, cheap, accretive bolt-ons concentrated in the better Winchester franchise: AMMO Inc. small-caliber assets (~$55.8M, April 2025; brass-casing vertical integration), White Flyer (2023), plus the Braskem EDC supply deal (November 2025) and JVs (Blue Water Alliance with Mitsui; Hidrogenii with Plug Power). Olin did not pour capital into more commodity chlor-alkali capacity, and the Beyond-250-driven rationalization (Freeport, Brazil Guarulhos) is sensible. This is the one disciplined element — dwarfed, though, by the buyback misallocation.

Incentive alignment (Fact). STIP = Adjusted EBITDA + Levered FCF; LTIP = 50% relative TSR + 50% net income (the performance-share metric shifts to Adjusted EBITDA from 2026, payout band widened to 0–240%). No ROIC/ROCE, no leverage/deleveraging, and no per-share value metric — a notable weakness for a company that just had to pledge collateral over leverage, and the shift to add-back-prone Adjusted EBITDA is a mild downgrade. 89% of CEO pay is at-risk; the ownership requirement is 6× salary. Relative TSR is the one per-share-adjacent metric.

The buyback post-mortem, quantified (Interpretation). The pro-cyclical critique deserves the numbers. Across 2021–2025 Olin retired ~52M shares for ~$2.66B — a ~30% reduction in the count (163M → 114.6M). But the timing was the inverse of value-creating: ~$1.35B (more than half the total) was spent in 2022 alone at ~$53/share, at the cycle’s earnings peak, and the annual spend then fell every single year as the stock declined — to $711M (2023), $300M (2024), and a token $51M (2025) at ~$23. With the stock now ~$24.50, the great bulk of that $2.66B was deployed above today’s price; the same dollars at today’s level would retire roughly twice the shares. And it was substantially debt-funded — net debt built toward ~$3.2–3.4B over the same window, which is the direct origin of the February-2026 secured amendment. The ~30% share-count reduction does concentrate any recovery (and the leverage convexity) onto fewer shares, which is the bull’s silver lining, but the capital was destroyed: Olin spent its financial flexibility buying high, then had to pledge its assets and freeze returns buying nothing at the low. This is the single clearest capital-allocation failure in the file, and the new comp plan — Adjusted EBITDA-based, with no leverage, ROIC, or per-share-value metric — does little to prevent its repetition.

Insider activity (Fact). CEO Ken Lane made a real open-market purchase of 7,250 shares (~$203K) on February 4, 2025 at the lows — the lone conviction signal — against CFO Todd Slater as a net seller (92,250 shares sold February 2026) and a low aggregate insider stake (~0.4–1.6%). Net insider behavior is weak/neutral with one bullish data point. The contrast with the absence of broader insider buying at a sub-$25 price the company itself calls a generational trough is notable: if management’s “much more leverage to come” narrative were a high-conviction view, one would expect a cluster of open-market purchases; instead there is one small CEO buy against routine grants and a CFO sale.

Verdict: a competent operator and a poor cyclical capital allocator. The debt-funded buyback torched optionality at the top and left Olin defending covenants with collateral at the bottom — the same pro-cyclical pattern as LYB, but worse because Olin carried the leverage into the trough and posted collateral. The redeeming features — a conservative, well-covered, long-held dividend; disciplined small Winchester bolt-ons; a real (if modest) Beyond-250 program; and a small CEO buy — are the offsets, not the headline. The new comp design does little to fix the incentive that produced the problem.

8. Changes and Headwinds — Last Two Years

Leadership (Fact). Scott Sutton (architect of the value model and the aggressive buyback) handed the CEO role to Kenneth T. Lane on March 18, 2024 in an orderly, planned transition. Lane joined from LyondellBasell (EVP Global Olefins & Polyolefins; previously 13 years at BASF) — notably, the same Ken Lane who departed LyondellBasell. CFO is Todd Slater. Lane has pivoted hard to balance-sheet defense and launched “Beyond 250.”

Capital structure (Fact). The February 2026 secured covenant amendment; the loss of investment grade (Fitch BB+, S&P BB, Moody’s Ba1); the buyback freeze; the ~$185M Shintech litigation cash payment.

Portfolio (Fact). The AMMO Inc. acquisition; the Braskem EDC deal; the Brazil Guarulhos closure; Freeport Chlorine-3 shutdown (Dec 2024); the Stade (Germany) epoxy supply contract; the Dow Freeport PO closure creating a ~$70M stranded-cost headwind (partly offset).

Cycle/macro (Fact). Decade-low chlor-alkali conditions; a FY2025 net loss; four straight Epoxy loss years; the failed China epoxy trade case; Winchester’s commercial destocking trough. Then the Q1-2026 Iran-war supply shock — a sharp, possibly transient, positive inflection (Asian vinyls force majeures, Q2-2026 EBITDA guided $160–200M) that management frames as durable and the sell-side doubts.

Verdict: the changes net to a forced strengthening of cost structure and a weakening of the balance sheet. Beyond 250, the portfolio rationalization, and the Winchester bolt-ons move the business toward a leaner, more focused producer; but the leverage, the secured amendment, the lost IG rating, and the goodwill/refinancing overhangs are real deteriorations, and the dominant variable (the ECU cycle, now distorted by the war) remains outside management’s control.

9. Risk Analysis

On the compounding of the dominant risks (Interpretation). Risks #1, #2, #3 and #5 are not independent — they chain, and the chain is the real danger. The sequence that matters is: the war premium (propping up H1-2026 EBITDA and covenant headroom) resolves in H2-2026 before a structural demand recovery arrives; CAPV reverts toward its Q1-2026 segment-loss run-rate; covenant-EBITDA drifts back toward the relaxed-covenant limit; the Q4-2026 goodwill test forces a CAPV/Epoxy write-down that compresses tangible equity and (depending on definitions) covenant capacity; the board cuts the dividend to conserve cash; and the ~$1.7B 2029–30 maturity wall approaches with leverage still ~4–5× and a sub-IG rating, so the refinancing clears at a punitive spread. None of these individually is fatal, but in sequence they describe a company that deleverages too slowly to escape its own balance sheet — the path in which the equity, a thin sliver beneath senior secured debt, is the residual that absorbs the damage. The mitigants are real but partial: Western rationalization and the cost-curve shift raise the EBITDA floor; the dividend is conservatively sized; the amendment bought relief to September 2027; and Winchester is a separable, saleable asset worth ~$2B that, covenant permitting, could be monetized to delever in extremis. The bull is betting the chain never starts because the cycle turns first; the bear is betting it does.

Catastrophic / total-loss risk (Interpretation). Higher than for LYB, but still not the base case. Olin is sub-IG and highly levered, with net debt senior to a thin equity, a 2029–30 refinancing wall, and a goodwill overhang — so a genuine tail of equity impairment/restructuring exists if the trough persists into the refinancing window. But Olin generated positive trough FCF (~$248M in 2025), holds ~$1.3B liquidity, just bought covenant relief through September 2027, and owns the separable, valuable Winchester franchise — so the realistic downside is a deep de-rating (bear ~$10, −60%+), not an imminent wipeout. The principal risk to capital is the combination of leverage and a prolonged trough, not a single operating event.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation. This section reverse-engineers what the market is pricing and stress-tests it.

Multiples now (Fact/Interpretation; EV ~$5.9–6.1B):

The cyclical optics: expensive-to-distressed on trough EBITDA, cheap (~4.2× EV/EBITDA, ~5.5× P/E) on mid-cycle. On its own decade, P/S sits at the 22nd percentile — cheaper than LYB’s 59th. The cheapness is earned risk premium for the leverage, not a free lunch; the ~9.8× tangible-book multiple flags the goodwill risk.

Embedded expectations (core, Interpretation). At $24.51 × 114.6M = $2.81B equity + ~$3.3B net debt = implied EV ~$6.1B. A levered, sub-IG, single-region commodity-chem producer warrants a lower through-cycle multiple than IG-rated LYB; at a 5.5–6.5× band, the market is capitalizing ~$0.95–1.1B of through-cycle EBITDA — i.e., only ~65–80% of the ~$1.4B normalized estimate. The market is pricing a partial, not full, recovery — a discount to mid-cycle, the sharp contrast with LYB (priced for a near-full recovery at $63). And despite the visible Q2-2026 war bump, the implied EBITDA stays ~$1.0B, suggesting investors are correctly looking through the transient windfall to a levered balance sheet that must survive to 2029–30.

The war-windfall bridge (Interpretation). It is worth quantifying how much of the gap between the ~$0.34B Q1-2026 annualized run-rate and the ~$1.4B normalized estimate the war could fill if it sticks. Q2-2026 EBITDA is guided to $160–200M — roughly double the ~$86M Q1 base — implying an annualized war-quarter run-rate of ~$0.7–0.8B. So the force-majeure spike (6–9% of global vinyls capacity, lifting EDC/caustic and steepening the cost curve toward US Gulf producers) plausibly adds ~$0.4B of annualized EBITDA at peak war pricing. Critically, that increment is the most perishable earnings Olin has: when Asian feedstock access normalizes and the idled capacity returns, the spike reverses. The durable residual is narrower — the cost-curve shift favoring US gas-advantaged producers, which was already Olin’s structural tailwind. The right way to read 2026, then, is that the war buys covenant headroom and refinancing optics through a dangerous window, but it should not be capitalized into mid-cycle EBITDA; the ~$1.35B base case deliberately excludes it.

The multiple debate (Interpretation). As with any cyclical, the scenario spread is driven as much by the multiple as by the EBITDA, and OLN’s multiple is doubly contestable because of the credit. Historically Olin traded ~5–7× forward EV/EBITDA; the sub-IG balance sheet, the secured amendment, and the 2029–30 wall argue for the low end or below (a levered equity deserves a lower EV multiple, because more of the EV is owed to lenders and the equity bears the refinancing tail). The bull argues the mix is improving (Winchester’s growing weight, Western rationalization) and that successful deleveraging would re-rate the multiple upward as the credit normalizes — a double-benefit (higher EBITDA and higher multiple and less debt subtracted) that is the source of the bull’s ~+176%. The bear argues that a permanently China-capped mid-cycle plus a stranded sub-IG credit deserves ~5× or less. A single turn of EV/EBITDA on ~$1.35B is ~$1.35B of EV — ~$12/share, roughly half the current price — so the multiple judgment is, by itself, worth more than the entire current equity value. The base 6.0× is deliberately mid-range, on the view that the deleveraging path is plausible but not yet proven.

Scenarios (Interpretation; net debt $3.3B, 114.6M shares):

• Bear: war fades by H2-2026; China keeps adding; Epoxy stays impaired; recovery slips; EBITDA ~$0.7–0.9B, multiple de-rates to ~5.5×, plus a goodwill impairment, a dividend cut, and refinancing stress. ~$10/share — below the 52-week low ($18), a scenario the market is not fully contemplating.
• Base: Western rationalization (OxyChem→Berkshire) + Beyond 250 + a normalizing ECU lift EBITDA to ~$1.3–1.4B by 2027–28; leverage falls toward ~2.5×; 6×. ~$42/share.
• Bull: war premium partly sticks + faster rationalization + full Beyond 250 + Winchester re-acceleration; EBITDA ~$1.6–1.8B, leverage <2×, multiple re-rates to ~6.5×. ~$68/share.

The leverage convexity (Interpretation). A ~2.1× EBITDA swing (bear → bull) produces a ~7× equity swing (~$10 → ~$68), because ~$3.3B of net debt sits senior to a ~$2.8B equity sliver (net debt ≈54% of EV; a 1% EV move ≈ 2.2% equity move). The equity is a deep, leveraged call: it can roughly triple off a genuine recovery or more than halve if the trough persists. Versus LYB, this is the higher-risk/higher-convexity version of the same trade — and, unlike LYB (priced at base), OLN still offers a discount to base.

Sum-of-the-parts (Interpretation). CAPV ~$0.95B × 5× = ~$4.8B; Winchester ~$0.23B × 8–10× = ~$1.8–2.3B (duopoly brand + Lake City contract + ~$1.33B backlog merits a defense/branded-consumer multiple); Epoxy ~$0–0.4B (impaired/option). SOTP ~$6.6–7.5B — above the traded EV (~$5.9–6.1B), implying the market over-discounts the leverage and/or under-credits Winchester’s separability (though the covenant currently bars asset sales). Winchester is genuine hidden value — modest but real.

Dividend at $0.80 (Fact/Interpretation). ~3.3% yield, covenant-frozen, ~2.7× trough-FCF-covered. Bear: the first lever to cut (2026 cash consumed by Shintech + Q1 loss). Base/bull: comfortably covered (~7–9×). Safe at mid-cycle, a bear casualty.

Reconciling the SOTP with the leverage (Interpretation). The sum-of-the-parts above (~$6.6–7.5B enterprise value vs. ~$5.9–6.1B traded) appears to say the whole company is undervalued — but the more useful reading is what it implies for the equity under different ownership of the leverage. If one credits Winchester at ~$2B and CAPV at ~$4.8B mid-cycle, the chemicals plus ammo are worth ~$6.6–7.5B as a going concern; subtract ~$3.3B of net debt and the implied equity is ~$3.3–4.2B, or ~$29–37/share — above the ~$24.50 spot even before any cyclical recovery, on mid-cycle segment marks. That gap is the market’s discount for (a) the risk that mid-cycle EBITDA never arrives (China caps it), (b) the covenant/refinancing tail, and © the fact that the covenant currently prevents Olin from surfacing Winchester’s value via a sale. In other words, the SOTP is not a free lunch — it is a statement that if Olin survives intact to mid-cycle, the equity is worth materially more than today, and the entire discount is compensation for the survival risk. That is the cleanest one-sentence framing of the investment: you are being paid a discount to mid-cycle SOTP to underwrite the balance-sheet tail.

Embedded-expectations verdict. Priced correctly: the war is transient (the market isn’t capitalizing it); the leverage discount is earned (the ~4.2× mid-cycle multiple vs. LYB’s ~6.5× compensates for the secured amendment, the maturity wall, and the goodwill overhang); the equity is a balance-sheet binary. Priced possibly incorrectly (variant): the degree of recovery (~65–80% of mid-cycle) may under-credit a genuine capital-cycle turn, and Winchester’s separability is under-credited (SOTP above EV). The dominant swing factor is where mid-cycle EBITDA settles and whether Olin survives intact to the 2029–30 refinancing — because net debt exceeds equity, the through-cycle EBITDA outcome and the credit path, not any operating nuance, determine whether the equity triples or halves.

11. Variant Perception

Consensus (Fact/Interpretation). Sell-side is mixed-to-cautious (analyst rating ~3.25/5 hold; targets ~$29, third-party color, not the author’s view), with a June-2026 Wells Fargo upgrade on the war/ECU supply-tightness thesis against a broadly skeptical backdrop. The most telling consensus signal is the short interest: ~11.7% of float (short ratio ~5.3) — meaningfully crowded short (vs. LYB’s ~4%), a clear variant-perception marker. Consensus accepts 2025 as the trough while doubting the recovery’s timing and questioning the balance sheet.

Strongest bull case. A deeply-discounted, highly-convex leveraged call on a genuine chlor-alkali capital-cycle turn (Western rationalization, OxyChem→Berkshire discipline, NA chlorine above prior troughs, the war pulling recovery forward), amplified by ~$3.3B of net debt so that a move to ~$1.4B mid-cycle EBITDA roughly triples the equity (~$42 base). Beyond 250 (+$100–120M in 2026) and a Winchester defense ramp add self-help; Winchester is separable hidden value; the SOTP sits above the traded EV; and the ~11.7% short is fuel for a squeeze on any data point confirming the turn. You are paid ~3.3% to wait, and you are buying below mid-cycle, not at it.

Strongest bear case. A sub-IG, over-levered commodity producer one covenant cycle from forced action, whose largest segment (CAPV) is segment-loss-making, whose second (Epoxy) is structurally impaired with no trade relief, and whose “value model” is narrative discipline that held index prices while earnings collapsed. The 2026 strength is an exogenous, reversible war spike; strip it out and EBITDA is ~$0.34B annualized. A goodwill impairment (Q4-2026), a dividend cut, and a punitive 2029–30 refinancing loom; the equity (~$2.8B) is a thin sliver under ~$3.3B of senior secured debt, worth ~$10 in a persistent trough. Management’s pro-cyclical record (buy high, lever up, pledge collateral at the bottom) compounds the risk.

The 3–5 assumptions that matter most:

1. Where mid-cycle EBITDA settles (~$1.4B vs. ~$0.8B) — does Chinese caustic supply permanently cap it?
2. Survival to the 2029–30 refinancing intact and at a non-punitive spread.
3. Durability of the war windfall vs. fade in H2-2026.
4. Whether the chlor-alkali turn is rationalization-led (durable) or war-noise (transient) — does OxyChem/Berkshire bring supply discipline?
5. Winchester’s trajectory (commercial recovery + military ramp) as the quality floor.

Falsification evidence: The bull breaks if H2-2026 ECU prices erode on war resolution while Chinese rates rise, EBITDA stuck ~$0.8B, and leverage stays ~4–5× into the refinancing. The bear breaks if realized (non-war) ECU values and operating rates climb on Western rationalization, EBITDA tracks to $1.3–1.4B, and Olin visibly deleverages toward ~2.5× — at which point the leverage convexity carries the equity toward the base case.

12. Fact vs. Interpretation Table

13. Open Questions

1. Where mid-cycle EBITDA truly settles post-rationalization — ~$1.4B, or capped toward ~$0.8–1.0B by Chinese caustic additions?
2. The 2029–30 refinancing — at what spread does ~$1.7B clear as secured sub-IG, and is the cycle turned by then?
3. Q4-2026 goodwill test — does it impair CAPV’s $1.28B and/or Epoxy’s $145M, and what does that do to covenant-EBITDA?
4. Durability of the 2026 war windfall into H2-2026 — the biggest near-term swing.
5. Dividend — at what trough-EBITDA does the board pre-emptively cut the $0.80 to defend the covenant?
6. Does OxyChem under Berkshire behave more disciplined on supply, lifting ECU value?
7. Winchester — Lake City renewal terms/margin and the NGSW ramp timing; can commercial pricing offset record copper?
8. Whether Olin elects early release of the collateral/covenant relief before September 2027 (a deleveraging signal) or runs it to term.

14. What Must Be True

For the BULL case to be right:

1. The chlor-alkali cycle turns on rationalization — Western closures + OxyChem/Berkshire supply discipline lift ECU values and operating rates, independent of the war.
2. Realized (non-war) mid-cycle EBITDA tracks toward $1.3–1.4B by 2027–28, with Beyond 250 (+$100–120M in 2026) and a Winchester recovery contributing; Olin visibly deleverages toward ~2.5×.
3. The 2029–30 maturity wall refinances at a non-punitive spread; no goodwill impairment forces covenant stress; the dividend holds.

Falsification test (bull breaks if): H2-2026 ECU prices erode on war resolution while Chinese operating rates rise, EBITDA is stuck at ~$0.8B into 2027, and leverage stays ~4–5×. Watch: NA chlorine/caustic index ex-war, confirmed Western closures vs. Chinese start-ups, and the leverage trajectory each quarter.

For the BEAR case to be right:

1. Chinese caustic additions permanently lower the ECU mid-cycle toward ~$0.8–1.0B EBITDA.
2. The war windfall fades by H2-2026 before demand recovers; Epoxy stays impaired; a goodwill impairment and a dividend cut arrive; the 2029–30 refinancing looms with leverage still ~4–5×.
3. The equity (~$2.8B), thin under ~$3.3B of senior secured debt, de-rates toward ~$10 as faith in the “bottom” and the balance sheet erodes.

Falsification test (bear breaks if): realized ECU values and operating rates climb through 2026–27 on rationalization (not war), EBITDA tracks to $1.3–1.4B, leverage falls toward ~2.5×, and the dividend is comfortably covered. Watch: sequential EBITDA improvement that survives a war resolution, and a visible deleveraging path.

The pivot: both cases turn on the same two variables — where mid-cycle EBITDA settles and whether Olin survives intact to the 2029–30 refinancing. Because net debt exceeds equity, the leverage makes both outcomes extreme: this is the rare deep-cyclical where the bull and bear are roughly equidistant in magnitude (~+70–180% vs. ~−60%), and the discount to base case is what tilts the asymmetry toward the long for risk-tolerant capital.

15. Source Appendix

(Full source detail in the Source Appendix below.) Primary sources: Olin FY2021–FY2025 Forms 10-K (CIK 0000074303), Q1-2026 Form 10-Q, 2026 DEF 14A proxy, Form 4 insider data, and 8-K material-event filings (the February-2026 credit amendment, Shintech verdict, dividend, AMMO Inc./Braskem). Management commentary: Olin earnings-call transcripts Q4-2024 through Q1-2026 (publicly available Q1-2026/Q4-2025/Q2-2025; gap quarters web-supplemented from public transcripts). Industry data: USITC (epoxy AD/CVD), SunSirs (caustic), NSSF/Ammoland (NICS), Wood Mackenzie/ICIS framing, copper price sources (cited inline, access date 2026-06-09). Cross-reference: a June-2026 LyondellBasell (LYB) companion analysis for the shared commodity-chemical capital-cycle frame. Quantitative cross-checks: SEC XBRL (EDGAR), public peer-multiple data, and third-party market-data aggregators (reconciled to filings). All management commentary is treated as hypothesis and validated against filings.

The body of this article (Sections 1–15) is deliberately position-free and contains no price target or buy/sell recommendation; the only subjective position appears in the clearly-labeled “Claude’s Take” block at the top, which is the author’s own independent opinion and general information only — not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Olin Corporation (NYSE: OLN) · As of 2026-06-09 · Supplemental to the analysis above. Fact / Interpretation / Assumption labels where material.

General

What thoughtful questions have other investors asked about this company? The dominant questions on 2025–2026 calls were: (1) the leverage trajectory (Mitsch/Andrews pressing trailing leverage “close to 4×”); (2) whether the “value-first” model is actually creating value (BofA’s DeYoe: the ECU index held near 2021 levels while EBITDA collapsed — “price stability with collapsed volume is not value creation”); (3) dividend safety under the leverage; (4) the durability of the 2026 war windfall (UBS’s Spector: “what pushes pricing higher from here?”); and (5) the epoxy losses and failed China trade case. The deepest question is whether mid-cycle EBITDA is still ~$1.4B or whether Chinese caustic additions have permanently lowered it.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? A deep low (Fact). FY2025 Adjusted EBITDA ~$0.62B vs. a 2021–22 peak ~$2.5B; GAAP net loss $(100.5)M; CAPV segment-negative in Q1-2026.

Driven by the external environment or internal actions? Overwhelmingly external (the chlor-alkali/ECU cycle and Chinese/European supply dynamics). Internal actions (value model, Beyond 250) soften but do not set the cycle.

How stable are revenues? Highly unstable (Fact): ~$6.1B–$9.4B across the cycle, driven by ECU price and epoxy margin, not volume.

Outlook for products/services? Cyclical chlor-alkali recovery expected 2027–28 (rationalization + demand); near-term distorted up by the 2026 war shock. Caustic is the stronger ECU side; epoxy structurally impaired; Winchester recovering.

How big will this market be — growing, shrinking, domestic or international? Global chlor-alkali ~53Mt caustic, growing slowly with GDP/industrial demand but oversupplied (China still adding). Ammunition is a domestic-share-gaining (tariff-protected) market with a growing military component.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Chlor-alkali: more competitive structurally (Chinese additions), though Western rationalization is a temporary offset. Ammunition: less (consolidating duopoly + tariff protection).

How profitable is the business (ROIC, ROE)? Through-cycle ROIC ~8–10% (near cost of capital), peak ROE ~50%, trough negative (Interpretation). Winchester is the higher-return exception.

How profitable is the industry — competitors, barriers to entry? Chlor-alkali is capital-destroying at the trough, with high capital/permitting barriers but no pricing power; ammunition is a profitable duopoly with brand/contract barriers.

Can the business be easily understood? Yes — the ECU and the value model are simple; ammunition is a brand + government-contract business.

Can it be undermined by foreign low-cost labor? Not labor (capital-intensive) but foreign low-cost capacity/subsidies — Chinese caustic/epoxy and energy-cost dynamics are the threat (chemicals); ammunition is tariff-insulated.

Do brands matter? Only in Winchester (the one brand moat) and marginally in epoxy formulated solutions; not in commodity chlor-alkali.

What is the nature of competition? Price (chemicals); brand/distribution/contract (ammunition).

Customers’ switching costs? Zero in commodity chlor-alkali/epoxy; real in Winchester’s Lake City/military relationship.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The Winchester brand and Lake City franchise are under-carried; conversely, $1.43B of goodwill (mostly CAPV) is at impairment risk (Q4-2026 test) — a potential over-statement.

Off-balance-sheet liabilities? The on-balance-sheet receivables facility (now pledged) is conservative presentation; watch pension (modestly underfunded ~$98M), environmental/legacy liabilities (Olin has large historical environmental reserves), and the Shintech ~$185M litigation payment.

How conservative is the accounting? Broadly conservative except on goodwill (carrying $1.43B against a segment-loss-making CAPV and chronically-loss-making Epoxy). Adjusted EBITDA (now the comp metric) adds back restructuring/non-recurring items — reconcile to the GAAP net loss.

How CapEx-hungry is the business? Very (capital-intensive electrolysis assets). Maintenance capex ~$200M+; FY2025 capex was only ~0.4× D&A — under-investing to protect FCF, borrowing from future reliability.

Capital Allocation & Management

How much FCF, how used, philosophy? Mid-cycle FCF ~$0.6–0.8B; trough ~$0.25B (negative in Q1-2026 with the Shintech payment). Philosophy was “value model + aggressive buyback” under Sutton; under Lane it has pivoted to balance-sheet defense (buybacks frozen, debt reduction prioritized).

Significant acquisitions recently? Small, disciplined bolt-ons into Winchester (AMMO Inc. ~$55.8M, 2025; White Flyer 2023) + the Braskem EDC supply deal (2025). No large M&A.

Buying back shares? Frozen (Fact) — ~$2.66B spent 2021–2025 (peak $1.35B at ~$53 in 2022, value-destructive), now covenant-frozen despite $1.95B authorization.

Issuing large amounts of new shares to insiders? No; routine equity grants only.

Compensation policy? STIP = Adjusted EBITDA + Levered FCF; LTIP = relative TSR + net income (→ Adjusted EBITDA from 2026, 0–240%). No ROIC/leverage/per-share metric — a weakness given the balance sheet.

Motivations of management? CEO Ken Lane (ex-LYB, since Mar-2024) is a commodity operator pivoting to deleveraging; one small CEO open-market buy (~$203K, Feb-2025) is the lone conviction signal against a low aggregate insider stake (~0.4%).

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — ordinary US common stock, standard 1099, no K-1 (Fact).

Dividend policy? $0.20/quarter ($0.80/yr, ~3.3% yield); 398 consecutive quarters; covenant-frozen at this level (no increases); ~2.7× trough-FCF-covered; a bear-case cut candidate.

How profitable is the business? See ROIC/ROE — peak-strong, trough-negative, ~cost-of-capital on average for the chemicals; Winchester higher.

Is net income diverging from cash from operations? FY2025 CFO (+$474M) far exceeded the GAAP net loss ($(100.5)M) — the gap is D&A (~$520M); no flattering-accruals red flag, but the 2025 CFO included a working-capital release that reverses on recovery.

Risks & Downside

What factors would cause the stock to decline? A covenant breach/forced action; a prolonged trough (China caps the ECU); the war windfall fading; a goodwill impairment; a dividend cut; a punitive 2029–30 refinancing. (See risk matrix.)

Risk of a catastrophic loss? A 60%+ drawdown (bear ~$10) is plausible if the trough persists; a genuine tail of equity impairment/restructuring exists if the cycle hasn’t turned by the 2029–30 refinancing.

Chance of a total loss? Low but non-trivial (higher than for an IG peer). Olin generates positive trough FCF, holds ~$1.3B liquidity, has covenant relief to Sep-2027, and owns the separable ~$2B Winchester asset — so total loss requires a multi-year failure to deleverage, not a single event.

Recent News & Events

Has the business environment changed recently? Twice (Fact): the cycle bottomed in 2025 at decade-low chlor-alkali conditions; then the Iran/Middle East war (~Feb 2026) spiked prices (Q2-2026 EBITDA guided $160–200M) — a possibly transient windfall. A Wells Fargo upgrade (June 2026) reflects the war/ECU-tightness thesis; a market-data news feed was otherwise quiet.

Significant acquisitions? AMMO Inc. (2025); no large deals.

Change in accounting policies? No policy change; the performance-share metric shifts to Adjusted EBITDA from 2026 (a comp, not accounting, change).

Recent changes — markets, facilities, management? Sutton→Lane CEO transition (Mar-2024); the February-2026 secured covenant amendment and loss of investment grade; Freeport Chlorine-3 shutdown; Brazil Guarulhos epoxy closure; the Stade (Germany) supply contract; the NGSW 6.8mm Lake City facility under construction.

APPENDIX B — Source Appendix

Olin Corporation (NYSE: OLN) · Research date 2026-06-09 · CIK 0000074303

Sources are listed primary-first. SEC filings are available from EDGAR; transcripts from company investor relations and public transcript providers. Management commentary is treated as hypothesis and validated against filings. Third-party feeds (public market-data aggregators) are convenience/cross-check sources reconciled to filings, never primary for US-filer financials.

1. SEC Filings — Primary (SEC EDGAR, CIK 0000074303)

2. Management Commentary — Earnings Call Transcripts

3. Industry & Market Data — Secondary (cited inline; access date 2026-06-09)

• USITC — epoxy AD/CVD termination (China negligibility; duties on Korea/Taiwan/Thailand only). https://www.usitc.gov/press_room/news_release/2025/er0430_66903.htm
• U.S. Commerce / trade.gov — epoxy final determinations. https://www.trade.gov/final-determinations-antidumping-duty-investigations-epoxy-resins-peoples
• SunSirs — China caustic soda 2025 review / 2026 outlook (capacity, utilization, price). https://www.sunsirs.com/commodity-news/petail-29471.html
• NSSF / Ammoland — 2025 NICS background checks (14.6M, −4.1% YoY); excise trends. https://www.ammoland.com/2025/05/background-checks-show-gun-sales-continue-slow-decline/
• market.us — global chlor-alkali market (Olin #1, capacity). https://market.us/report/global-chlor-alkali-market/
• ChemAnalyst — caustic soda / liquid chlorine pricing (electricity cost share). https://www.chemanalyst.com/Pricing-data/liquid-chlorine-45
• Investing News — copper price (record 2026 highs). https://investingnews.com/daily/resource-investing/base-metals-investing/copper-investing/highest-price-for-copper/
• JE Dunn — Lake City NGSW 6.8mm facility topping-out. https://jedunn.com/blog/topping-out-marks-progress-on-new-ammunition-faciliy-at-lake-city-plant/
• Rating actions — Fitch downgrade to BB+ (Feb-2026). https://uk.marketscreener.com/news/fitch-downgrades-olin-corporation-to-bb-outlook-negative-ce7e5dd2df88f124

4. Quantitative Cross-Checks — Convenience/Third-Party (reconciled to filings)

• SEC EDGAR XBRL — authoritative US-filer facts.
• Public market data — price, market cap, EV, multiples, peer comps (WLK, DOW, LYB, KRO, RGR). Reconciled to filings.
• third-party fundamentals data — multi-period statements, snapshot, valuation index (own-history percentiles: P/B 44th, P/S 22nd, composite 33rd). Third-party aggregate; reconciled to 10-K. Note: third-party data FY2023 gross-profit field was glitched and ignored.
• third-party news aggregation — returned no “important” items for OLN; web supplemented the rating actions and Wells Fargo upgrade.

5. Analytical Frameworks

• Greenwald & Kahn, “Competition Demystified” — barriers-to-entry / genuine-advantage taxonomy; market-share-stability and ROIC tests (applied in–: CAPV survivorship cost advantage vs. Winchester moat).
• Marathon / Chancellor, “Capital Returns” — supply-side capital-cycle analysis (applied in as the central chlor-alkali lens).

6. Cross-Read

• A June-2026 LyondellBasell (LYB) companion analysis — shared commodity-chemical capital-cycle frame; OLN is the smaller, more-levered, higher-convexity version.

All figures cross-checked against primary filings where possible. Where only third-party data was available (peer multiples, third-party data aggregates), the source is labeled convenience data, not primary. Two reconciliations made against the 10-K: FY2025 net loss = $(100.5)M (EPS $(0.88)); 2022 buyback average ≈ $53/share. Price/market data as of 2026-06-09.